Cell And Gene Therapy Manufacturing

1. Isolating CD4 / CD8 T Cells For Improved Drug Efficacy, Productivity 6/2/2025

   Learn how the active detachment of dynabeads from target cells at any time allows users to add flexibility and scalability to their process.

2. A Collaboration With Zurich University Of Applied Sciences 5/19/2025

   Explore ZHAW’s pioneering work and collaboration in cell cultivation and bioprocessing to deliver scalable, high-performance solutions that address key challenges in biomanufacturing scale-up.

3. Key Considerations For Rapid Microbial Methods For Mycoplasma Detection 5/29/2025

   Learn the importance of demonstrating product specific suitability, defining representative sample, consistent sampling protocols, accommodating volume and turnaround time constraints, and the need to establish equivalence.

4. Process Liquids And Buffers Offering 5/2/2024

   Whether you are a researcher, scientist, or industry professional, this video will provide valuable insights into our large volume liquids manufacturing capabilities.

5. Technology Needs For Automated Manufacturing 8/18/2023

   Investigate the importance of technology as it relates to automation and standardization within cell therapy manufacturing. The panelists in this discussion cover solutions and services needed for process automation in CGT.

6. How Past Gene Therapy Approvals Are Shaping the Future with Dr. Peter Marks 1/30/2024

   In this segment of Cell & Gene Live, Dr. Peter Marks shared what he and his team have learned from current gene therapy approvals to accelerate future approvals.

7. CaptureSelect™ Technology - Powerful Affinity For More Streamlined Purification 11/4/2025

   Replace inefficient chromatographic steps with high-specificity affinity ligands to streamline downstream processing. This approach simplifies workflows and protects sensitive biomolecules.

8. Manufacturing Hurdles With Viral Vectors 11/13/2023

   With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

9. Efficient AAV Purification With AAVx And AAV9 Magnetic Beads 6/30/2025

   Explore an alternative to chromatographic affinity capture that eliminates the need for universal nuclease treatment by utilizing magnetic beads with ligands specific to AAV.

10. Race To The Regulatory Finish Line: Dr. Nicole Verdun Talks Efficiencies In Platform Technologies 1/30/2024

    Could a platform approach help certain therapies make their way over the regulatory finish line more efficiently?